Published in Vaccine Weekly, October 9th, 2002
"Despite an abundance of preclinical data, relatively little is known regarding the efficacy of DNA vaccination in humans," the authors of a recent University of Alabama at Birmingham vaccine trial pointed out.
Patients given a plasmid-encoded vaccine combining hepatitis B surface antigen (HBsAg) and carcinoembryonic antigen (CEA) responded well to the vaccine's viral antigen, but showed little clinical response to the cancer antigen, according to Robert M. Conry and coauthors, who are investigators in the Divisions of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly